Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-22T15:06:40.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Usefulness of seroconversion rates for comparing infection pressures between countries

Published online by Cambridge University Press:  12 April 2010

J. SIMONSEN ,
P. TEUNIS ,
W. VAN PELT ,
Y. VAN DUYNHOVEN ,
K. A. KROGFELT ,
M. SADKOWSKA-TODYS  and
K. MØLBAK
J. SIMONSEN*
Affiliation:
Division of Epidemiology, Statens Serum Institut, Copenhagen, Denmark
P. TEUNIS
Affiliation:
Epidemiology and Surveillance Unit, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands Hubert Department of Global Health, Rollins School of Public Health, Emory University, AtlantaGA, USA
W. VAN PELT
Affiliation:
Epidemiology and Surveillance Unit, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Y. VAN DUYNHOVEN
Affiliation:
Laboratory for Zoonoses and Environmental Microbiology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
K. A. KROGFELT
Affiliation:
Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark
M. SADKOWSKA-TODYS
Affiliation:
Department of Epidemiology, National Institute of Public Health – National Institute of Hygiene, Warszawa, Poland
K. MØLBAK
Affiliation:
Division of Epidemiology, Statens Serum Institut, Copenhagen, Denmark
*
*Author for correspondence: J. Simonsen, M.Sc., Division of Epidemiology, Statens Serum Institut, Artillerivej 5, DK-2300Copenhagen S, Denmark. (Email: [email protected])
Rights & Permissions [Opens in a new window]

Summary

Salmonella is a frequent cause of foodborne illness. However, since most symptomatic cases are not diagnosed, the true infection pressure is unknown. Furthermore, national surveillance systems have different sensitivities that limit inter-country comparisons. We have used recently developed methods for translating measurements of Salmonella antibodies into estimates of seroincidence: the frequency of infections including asymptomatic cases. This methodology was applied to cross-sectional collections of serum samples obtained from the general healthy population in three European countries. Denmark and The Netherlands had the lowest seroincidence (84169 infections/1000 person-years), whereas Poland had the highest seroincidence (547/1000 person-years). A Bayesian method for obtaining incidence rate ratios was developed; this showed a 6·3 (95% credibility interval 3·3–12·5) higher incidence in Poland than in Denmark which demonstrates that this methodology has a wider applicability for studies of surveillance systems and evaluation of control programmes.

Keywords

ELISAmathematical modellingsalmonellosisserology
Type
Original Papers
Information
Epidemiology & Infection , Volume 139 , Issue 4 , April 2011 , pp. 636 - 643
Copyright
Copyright © Cambridge University Press 2010

INTRODUCTION

A general problem with infectious disease surveillance systems is that due to under-ascertainment, estimation of incidences based on numbers of reported laboratory-confirmed cases will often lead to considerable underestimation. This is especially true for self-limiting diseases with symptoms such as diarrhoea caused by foodborne bacteria [Reference Herikstad1]. Several barriers have to be crossed before an infected person is reported in a surveillance system, e.g. the person has to seek healthcare, a stool sample has to be taken, the bacteria should be identified by a laboratory [Reference Scallan2], and the laboratory should report the positive finding. A Dutch study has estimated that only one out of 14·3 Salmonella cases in the general population was reported to the laboratory surveillance system [Reference van Pelt3]. Since both the organization of healthcare and surveillance systems differ strongly between countries, the numbers of reported cases cannot be used to compare incidences as a measure for the disease burden across countries. Clearly we are in need of alternative, less biased methods to evaluate the incidence of salmonellosis and other diseases since official systems only capture a small and unknown fraction of case patients.

Community studies have been used in an attempt to estimate the true burden of gastroenteritis by use of questionnaires and the microbiological analysis of systematically collected stool samples from prospectively followed population cohorts [Reference van Pelt3, Reference Wheeler4]. However, such community studies are very expensive and may therefore be difficult to apply in most countries. In the current study we use measurements of antibodies in representative serum samples randomly selected from the population to estimate the frequency of seroconversions against a certain pathogen. We show that these can be used to obtain a valid comparison of infection pressure between countries. This approach also benefits from being more cost-effective than traditional studies involving the collection of faecal samples, since it can use sera from well-defined cohorts collected for other purposes.

Blood samples from cross-sectional population studies in three European countries were gathered as part of a European collaborative project [5]. After measuring antibodies against Salmonella we were able to estimate the incidence of Salmonella seroconversions in the participating countries and make comparisons. The method presented here has the advantage of being completely independent of the healthcare and surveillance systems and is therefore well suited for comparing the incidence of Salmonella exposures between countries and periods. Moreover, this methodology can provide a basis for estimating the degree of underreporting, e.g. evaluating the ratio (sometimes referred to as the multiplier estimate [Reference Voetsch6]) between the seroincidence and the incidence of culture-confirmed cases.

We applied a mathematical model from a previously published study aimed at estimating the frequency of seroconversions [Reference Simonsen7], a measure termed as the seroincidence. Our paper will show the results of applying this method to estimate the seroincidence in cohorts from different countries and periods. We further extended the model such that the ratio (with corresponding credible intervals) between pairs of incidences could be estimated.

METHODS

Materials

Longitudinal study

A follow-up study of 302 persons infected with either Salmonella Enteritidis or Salmonella Typhimurium was performed [Reference Strid8]. Blood samples were taken three or four times in a period of 18 months after onset of infection. Anti-Salmonella IgA, IgM and IgG concentrations were measured in arbitrary units of optical density (OD) values in an in-house mixed ELISA, using lipopolysaccharides of S. Enteritidis+ S. Typhimurium as capture antigens [Reference Strid8].

Cross-sectional studies

Population-representative sera were collected in three countries: Denmark, Poland and The Netherlands. The Danish sera were obtained from the Helbred 2006 cohort and consisted of 1780 blood samples collected in 2006 and 2007. The Polish sera came from Bank Surowic Zakladu Wirusologii PZH and consisted of 500 samples collected in 2004 [Reference Smith9]. In The Netherlands we included sera from two cohorts: the first was the Regenboog cohort for which 1053 blood samples were collected in 1998–2002 while the second, the Pienter II cohort [Reference van der Klis10], consisted of 1065 blood samples collected in 2006 and 2007.

Antibody titres in each blood sample from the cross-sectional samples were measured in the same units by the same assay as in the longitudinal study.

Estimation of seroprevalence

In order to define the threshold for being seropositive, the 95% percentile was calculated for each of the antibody classes (IgG, IgM, IgA) in the Danish cross-sectional cohort and these values were used as cut-offs. The antibody levels observed in the three other countries were then compared with this cut-off value. The seroprevalence in each of the four cohorts was estimated by the fractions of seropositive samples. This was done separately for each of the three antibody classes (IgG, IgM, IgA).

Estimation of seroincidence

The seroincidence is here defined as the number of seroconversions per (1000) number of person-years. Under the assumption of a rapid rise in antibody levels following infection and a subsequent slow decay, we designed a mathematical model. In order to handle individual variation of peak level, decay rate and baseline level, the model had a two-level hierarchical structure where the parameters describing the individual response curves were allowed to be random components with global mean and variance parameters. Inference of these parameters was obtained from the longitudinal study [Reference Simonsen7]. Using the estimated parameters it was then possible to predict the antibody level for any number of days since a person experienced their last infection. Conversely, given a set of antibody measurements (IgG, IgM, IgA), it is then possible to back-calculate the time elapsed since a last infection. This was done by Monte Carlo simulation, producing sets of time since infection, {T i}j, where j refers to any individual simulation and i to an individual in any of the cross-sectional samples.

A Bayesian approach was used for the estimation of seroincidence. This means that we considered the seroincidence as a random variable of which we aimed to find the conditional distribution (commonly called the posterior distribution) given the observed data. A requirement for doing so is definition of a distribution of the model parameter(s) prior to any observations (the prior distribution). In a situation with no prior information (which most often is the case) it is often possible to define a non-informative prior distribution reflecting complete ignorance about the model parameters. Then the posterior distribution depends (entirely) on the information contained in the observed data.

The approach used here is explained in detail in Simonsen et al. [Reference Simonsen7]. Inference of the incidence is based on the posterior distribution of the incidence given the observed antibody values. Since an incidence is treated as a scale parameter, the non-informative prior distribution should be flat on the log-scale. Therefore, the non-informative prior distribution of the incidence is given by the improper probability density function, π(γ) ∝ 1/γ, where γ is the unknown incidence.

We assumed first that the times since infection are known (T i for individual i) for each individual in the cross-sectional cohorts. Due to the fact that the antibody levels for IgM and IgA appeared to reach steady state after 60 days, we chose to censor estimated time since infection at 60 days [Reference Simonsen7]. The conditional distribution of incidence given the time values is then given by

(1)
\eqalign{ p\,\lpar \gamma \vert T_{\setnum{1}} \comma \cdots \comma T_{N} \rpar \tab \propto \pi \,\lpar \gamma \rpar \prod\limits_{i \equals \setnum{1}}^{N} {p\,\lpar T_{i} \vert \gamma } \rpar \cr \tab \equals \pi \,\lpar \gamma \rpar \prod\limits_{i \equals \setnum{1}}^{N} {\gamma ^{\setnum{1}_{{T_{i} \lt \setnum{60}}} } {\rm e}^{ \minus \gamma \min \lpar T_{i}\comma \setnum{60}\rpar } } \cr \tab \equals \gamma ^{\left( {\sum\nolimits_{{i \equals \setnum{1}}}^{N} {\setnum{1}_{{T_{i} \lt \setnum{60}}} } } \right) \minus \setnum{1}} {\rm e}^{ \minus \gamma \sum\nolimits_{{i \equals \setnum{1}}}^{N} {\min \lpar T_{i} \comma \setnum{60}\rpar } } \cr}

where 1T i<60 takes the value 1 if individual i was infected within the last 60 days and zero otherwise. Note that the last term shows that γ is Gamma-distributed (after conditioning with time since infection). This implies that the mean value (which can be used as an estimate) of γ is

{{\sum\nolimits_{i \equals \setnum{1}}^{N} {1_{T_{i} \lt \setnum{60}} } } \over {\sum\nolimits_{i \equals \setnum{1}}^{N} {\min \lpar T_{i} \comma 60\rpar } }}\comma

which intuitively is correct; the number of observed events divided by the total observed time between infection/censoring event and observation event is the commonly used estimator of an incidence.

However, only the antibody values are known – not the actual time since infection. To overcome this problem, we can simulate sets of the time since infection from their conditional distribution given the observed antibody values averaging over the distributions where we condition with the simulated time values. These simulations were performed by construction of a Markov Chain [Reference Gilks, Richardson and Spiegelhalter11]. The posterior distribution of the incidence is therefore

(2)
\eqalign{ p\lpar \gamma \vert {\rm data}\rpar \tab \equals E_{\lcub T_{i} \rcub _{N} \vert {\rm data}}\; p\lpar \gamma \vert \lcub T_{i} \rcub \comma {\rm data}\rpar \cr \tab \equals E_{\lcub T_{i} \rcub \vert {\rm data}} \;p\lpar \gamma \vert \lcub T_{i} \rcub \rpar \cr \tab \approx {1 \over M}\sum\limits_{j \equals \setnum{1}}^{M}\, {p\lpar \gamma \vert \lcub T_{i} \rcub _{j} \rpar \hfill \hskip92pt

where {T i} (with no subscript j) refers to the unknown random variable time since infection while {T i}j refers to the jth simulated set of values of time since infection and M is the number of simulated sets of time since infection. The second part of equation (2) follows from the fact that for given values of time since infection, antibody levels do not provide any further information about the incidence. Convergence of the Markov chains was tested by verifying that there were no significant differences between different parts (of various sizes) of the chains (Geweke's test) [Reference Gilks, Richardson and Spiegelhalter11, Reference Dodds and Vicini12]. We especially verified if the selected burn-in period was long enough by testing for significant difference between samples in the initial part of Markov chains directly after the burn-in period (the burn-in period was the initial 5000 iterations in the chain, that were discarded) and samples in the final part of the chain. Further, the Markov chains were thinned in order to approach independent samples. This was done by verifying that all the autocorrelations in the thinned chains were insignificantly different from zero.

By using equation (1) it can be seen that the posterior distribution of the incidence can be estimated by a mixture of Gamma distributions. Note that the observed antibody values only affect the posterior distribution through the simulated time values which were simulated in the conditional distribution given the antibody levels.

The distribution given by equation (2) allows estimation of the median incidence as well as 95% credibility intervalsFootnote † as the 2·5% and 97·5% percentiles.

Incidence comparison

Pairwise comparisons of the seroincidences between the four cohorts were made by constructing the posterior distribution of the incidence rate ratios. The posterior distribution of the ratio of two incidences could be constructed analytically. After calculating the posterior distribution of the incidence in the two countries under consideration, we simply need to find the distribution of the ratio of two random variables which are distributed as the posterior distributions of the pairs of incidences from the two countries.

We assumed that X and Y are two independent stochastic variables which are both Gamma-distributed with shape and scale parameters (αX, λX) and (αY, λY), respectively.

The distribution of the ratio of two stochastic variables, X and Y can be calculated as

f_{X\sol Y} \,\lpar z\rpar \equals \int {yf_{X} \lpar zy\rpar\, f_{Y} }\, \lpar y\rpar\, {\rm d}y\comma

where the f X and f Y are probability mass functions for the stochastic variables X and Y. When both X and Y are Gamma-distributed the following distribution is obtained for their ratio:

(3)
\eqalign{ f_{X\sol Y} \, \lpar z\rpar \tab \equals \int_{\setnum{0}}^{\infty } {y{{\lambda _{X} ^{\alpha _{X} } \lpar zy\rpar ^{\alpha _{X} \minus \setnum{1}} {\rm e}^{ \minus \lambda _{X} zy} } \over {\rmGamma \lpar \alpha _{X} \rpar }}{{\lambda _{Y} ^{\alpha _{Y} } y^{\alpha _{Y} \minus \setnum{1}} {\rm e}^{ \minus \lambda _{Y} y} } \over {\rmGamma \lpar \alpha _{Y} \rpar }}{\rm d}y} \cr \tab \equals {{\rmGamma \lpar \alpha _{X} \plus \alpha _{Y} \rpar } \over {\rmGamma \lpar \alpha _{X} \rpar \rmGamma \lpar \alpha _{Y} \rpar }}\lambda _{X} ^{\alpha _{X} } \lambda _{Y} ^{\alpha _{Y} } z^{\alpha _{X} \minus \setnum{1}} \lpar \lambda _{Y} \plus \lambda _{X} z\rpar ^{ \minus \alpha _{X} \minus \alpha _{Y} }. \cr}

In the present case, X and Y, represent the incidences in two different countries that are not Gamma-distributed but rather mixtures of Gamma-distributed variables:

X \equals {1 \over M}\sum\limits_{i \equals \setnum{1}}^{M} {X_{i} } \quad {\rm and}\quad Y \equals {1 \over M}\sum\limits_{i \equals \setnum{1}}^{M} {Y_{i} } \comma

where X i and Y i are, respectively, Γ(αXi, λXi) and Γ(αYi, λYi) distributed.

The distribution of f X/Y(z) is therefore given by probability mass function of the form

{1 \over {M^{\setnum{2}} }}\sum\limits_{j \equals \setnum{1}}^{M} {\sum\limits_{i \equals \setnum{1}}^{M} {f_{Xj\sol Yi} } \lpar z\rpar } \comma

where f Xi/Yi(z) is given by equation (3).

Using this distribution, median values and 95% credibility intervals can be calculated for the incidence rate ratios.

Applied software

The Markov chain used for estimating the longitudinal parameters was produced in WinBugs [Reference Lunn13]. We wrote our own procedures for constructing the Markov chains for estimating the time since infection, the posterior distributions of the incidence rates, and the posterior distributions of the incidence rate ratios as we were unable to find software capable of performing these tasks. This was done in SAS language [14].

RESULTS

Seroprevalences

The distributions of the observed OD values are shown in Figure 1. For all three antibody types the samples from Poland had the largest fraction of high OD values (⩾0·4) while Denmark had the lowest fraction of high OD values. Crude seroprevalence estimates in each of the three cross-sectional samples are shown in Table 1. The seroprevalence was lowest in Denmark (5% per definition) while the highest prevalence was found in the Polish cohort (39·8%, 20·6%, 17·0% positive samples for IgG, IgM and IgA, respectively); The Netherlands had intermediate values.

Fig. 1. Distribution of optical density (OD) values for each of the four of serum sample collections. ▪, Denmark (2006–2007); □, The Netherlands (2006–2007); , The Netherlands (1998–2002); , Poland (2004).

Table 1. Estimated seroprevalences and seroincidences in the participating countries

Seroincidences

Trace plots and Geweke's tests did not give any indication that convergence of the Markov chains were not attained (data available as Supplementary online material). Further, plots showing goodness-of-fit are shown in Simonsen et al. [Reference Simonsen7]. The posterior distribution of seroincidence is shown in Figure 2 and summarized by median (as a point estimate) and 95% credibility intervals (95% CI) in Table 1. The ordering followed the same pattern as the seroprevalences. The Polish incidence estimate was 547 infections/1000 person-years (95% CI 343–813), corresponding approximately to one seroconversion every second year, while the lowest incidence was in the Danish cohort where it was estimated that on average 84 (95% CI 41–141) seroconversions took place per 1000 person-years, i.e. one seroconversion every 12 years. Seroincidence estimates for the two Dutch serum collections were very similar.

Fig. 2. Posterior density functions of the seroincidence in the participating countries. –––, Denmark; , The Netherlands (2006–2007); – – –, The Netherlands (1998–2002); ……, Poland.

Incidence comparisons

Incidence rate ratios with 95% credibility intervals are shown in Table 2. The seroincidence in Poland was significantly higher than in the two Dutch cohorts and the Danish cohort. The largest difference was found between the Polish and the Danish cohort: 6·34 (95% CI 3·31–12·53) infections in Poland per infection in Denmark. Incidence estimates calculated on base of the two Dutch cohorts, which were sampled 6–7 years apart, were both higher than the Danish incidence (ratio 2·01 for Regenboog, 1·74 for Pienter) but this was not statistically significant.

Table 2. Estimated incidence rate ratios with 95% credibility intervals between the four cohorts. These are found by taking medians, 2·5% and 97·5% percentiles from the posterior distributions of the incidence rate ratios

DISCUSSION

This paper shows how seroincidence can be estimated and how this measure can be used to compare Salmonella infection rates between countries. The use of seroincidence has several benefits compared to the more commonly used seroprevalence. First, the magnitudes of the seroprevalences are dependent on the arbitrary choice of cut-off for being defined as seropositive.

Further, since the persistence of antibodies varies between individuals, any given seroprevalence cannot be converted into a frequency of infection by simple means. Finally, the three types of antibodies (IgG, IgM, IgA) each produce an estimate of seroprevalence, and these three estimates are difficult to combine. In contrast the seroincidence does not suffer from such problems with arbitrary cut-off levels for different antibody types. Further, as seroincidence is based on serum antibody titres measured with the same ELISA in all sera, it does not suffer from the biases present in the numbers of laboratory-reported cases from different nations, and can therefore be used to compare the sensitivity of surveillance systems between countries or periods.

It is important to emphasize that both symptomatic as well as asymptomatic infection can lead to seroconversion; therefore, the seroincidence shown in this paper should not be seen as a measure of frequency of disease, but rather a measure of frequency of Salmonella exposures leading to seroconversion. However, as this is likely to reflect the exposure at the population level to this foodborne agent, it might be applicable to evaluate the effect of control programmes between countries.

In general, it seems that the higher the seroincidence, the more the IgG-based seroprevalence exceeds the two others (IgM- and IgA-based seroprevalence). Most extreme was the Polish seroprevalence which varied from 17·0% for IgA to 39·8 for IgG. IgG antibodies decay more slowly than IgM and IgA antibodies and therefore, if incidence is high, IgG antibodies tend to persist while IgA and IgM antibodies may decrease between subsequent infections.

When comparing the estimated seroincidences in the two Dutch cohorts we saw a decline over the period from 169 to 149 cases/1000 person-years. The same pattern was found in the incidence of reported cases which had a decline from 0·18 to 0·14 cases/1000 person-years. However, the study also shows that the annual number of reported cases can lead to a very skewed interpretation of the actual infection pressure. While we observed a ratio of seroincidence rates between Poland and Denmark of 6·34 (Table 2), the incidence of reported cases in the two countries was 0·42 cases and 0·29 cases/1000 person-years, respectively, which gives a rate ratio of 1·44. This underlines that inter-country comparisons based on officially reported surveillance figures and seroincidence ratios have a completely different interpretation. Our methodology – which in the current study has been extended to include formal comparisons of seroincidence between countries – offers an attractive alternative approach that can be used to evaluate surveillance systems and control programmes.

NOTE

Supplementary material accompanies this paper on the Journal's website (http://journals.cambridge.org/hyg).

ACKNOWLEDGEMENTS

The study was partly financially supported by MED-VET-NET, an EU Network of Excellence for research on the prevention and control of zoonoses (EU contract no. FOOD-CT-2004-506122), the Danish Graduate School of Biostatistics and the Faculty of Health Science, Copenhagen University.

The work by P.T. was funded by POLYMOD, EU-FP6 contract no. SSP22-CT-2004-502084. We are very grateful to Dinna Krüger and Tina Hansen, Serological Laboratory, SSI for their careful work and to Gerhard Falkenhorst, Division of Epidemiology, SSI, for his help with administration of the project.

DECLARATION OF INTEREST

None.

Footnotes

† In a Bayesian framework, ‘credibility intervals’ are the commonly used term for intervals showing the accuracy of the estimates. Basically, these are equivalent to confidence intervals.

References

REFERENCES

1.Herikstad, H, et al. A population-based estimate of the burden of diarrhoeal illness in the United States: FoodNet, 1996–1997. Epidemiology and Infection 2002; 129: 9–17.CrossRefGoogle Scholar
2.Scallan, E. Activities, achievements, and lessons learned during the first 10 years of the Foodborne Diseases Active Surveillance Network: 1996–2005. Clinical Infectious Diseases 2007; 44: 718–725.Google ScholarPubMed
3.van Pelt, W, et al. Laboratory surveillance of bacterial gastroenteric pathogens in the Netherlands, 1991–2001. Epidemiology and Infection 2003; 130: 431–441.CrossRefGoogle ScholarPubMed
4.Wheeler, J, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. British Medical Journal 1999; 318: 1046–1050.CrossRefGoogle ScholarPubMed
5.MedVetNet Workpackage 32. 26 September 2006 (http://www.medvetnet.org/cms/templates/doc.php?id=92). Accessed 23 November 2009.Google Scholar
6.Voetsch, A, et al. FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clinical Infectious Diseases 2004; 38: S127–S134.CrossRefGoogle ScholarPubMed
7.Simonsen, J, et al. Estimation of incidences of infectious diseases based on antibody measurements. Statistics in Medicine 2009; 28: 1882–1895.CrossRefGoogle ScholarPubMed
8.Strid, MA, et al. Kinetics of the human antibody response against Salmonella enterica serovars Enteritidis and Typhimurium determined by lipopolysaccharide enzyme-linked immunosorbent assay. Clinical and Vaccine Immunology 2007; 14: 741–747.CrossRefGoogle ScholarPubMed
9.Smith, JS, et al. Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland. Sexually Transmitted Infections 2006; 82: 159–163.CrossRefGoogle ScholarPubMed
10.van der Klis, FR, et al. Second national serum bank for population-based seroprevalence studies in the Netherlands. The Netherlands Journal of Medicine 2009; 67: 301–308.Google ScholarPubMed
11.Gilks, WR, Richardson, S, Spiegelhalter, DJ. Markov Chain Monte Carlo in Practice. London: Chapman & Hall/CRC, 1996, pp. 1–15.Google Scholar
12.Dodds, MG, Vicini, P. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics. Annals of Biomedical Engineering 2004; 32: 1300–1313CrossRefGoogle ScholarPubMed
13.Lunn, DJ. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10: 325–337.CrossRefGoogle Scholar
14.SAS. SAS version 9.1 for Windows. SAS Institute, Cary, NC, USA, 2002–2003.Google Scholar
Figure 0

Fig. 1. Distribution of optical density (OD) values for each of the four of serum sample collections. ▪, Denmark (2006–2007); □, The Netherlands (2006–2007); , The Netherlands (1998–2002); , Poland (2004).

Figure 1

Table 1. Estimated seroprevalences and seroincidences in the participating countries

Figure 2

Fig. 2. Posterior density functions of the seroincidence in the participating countries. –––, Denmark; , The Netherlands (2006–2007); – – –, The Netherlands (1998–2002); ……, Poland.

Figure 3

Table 2. Estimated incidence rate ratios with 95% credibility intervals between the four cohorts. These are found by taking medians, 2·5% and 97·5% percentiles from the posterior distributions of the incidence rate ratios

Supplementary material: PDF

Simonsen supplementary material

Data 1.pdf

Download Simonsen supplementary material(PDF)
PDF 1.1 MB
Supplementary material: PDF

Simonsen supplementary material

Data 2.pdf

Download Simonsen supplementary material(PDF)
PDF 1.2 MB
Supplementary material: PDF

Simonsen supplementary material

Data 3.pdf

Download Simonsen supplementary material(PDF)
PDF 1.1 MB
Supplementary material: File

Simonsen supplementary material

Table.doc

Download Simonsen supplementary material(File)
File 42 KB